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Abstract
This study aimed to evaluate the effects of hormone
replacement therapy (HRT), known to prevent osteoporosis and
fractures, on markers of bone and cartilage metabolism.
Furthermore, we assessed whether changes in these markers
corresponded to alterations in bone mineral density and
radiographic joint destructions in postmenopausal women with
rheumatoid arthritis. Eighty-eight women were randomized to
receive HRT, calcium, and vitamin D3, or calcium and vitamin D3
alone, for 2 years. Bone turnover was studied by analyzing
serum levels of C-terminal telopeptide fragments of type I
collagen (CTX-I), C-terminal telopeptide of type I collagen
(ICTP), bone sialoprotein, and C-terminal propeptide of type I
procollagen (PICP) and cartilage turnover by urinary levels of
collagen type II C-telopeptide degradation fragments (CTX-II)
and cartilage oligomeric matrix protein (COMP) in serum.
Treatment with HRT resulted in decrease in CTX-I (P < 0.001),
ICTP (P < 0.001), PICP (P < 0.05), COMP (P < 0.01), and
CTX-II (P < 0.05) at 2 years. Reductions in CTX-I, ICTP, and
PICP were associated with improved bone mineral density. Of
the markers tested, CTX-I reflected bone turnover most
sensitively; it was reduced by 53 ± 6% in the patients receiving
HRT. Baseline ICTP (P < 0.001), CTX-II (P < 0.01), and COMP
(P < 0.05) correlated with the Larsen score. We suggest that
biochemical markers of bone and cartilage turnover may provide
a useful tool for assessing novel treatment modalities in arthritis,
concerning both joint protection and prevention of osteoporosis.
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Introduction
Rheumatoid arthritis is characterized by cartilage destruc-
tion, bone erosions, periarticular osteoporosis, and gener-
alized bone loss resulting in increased prevalence of
osteoporotic fractures [1,2]. Some of the disease mecha-
nisms responsible for focal bone loss may be similar to
processes of generalized osteoporosis and associated
with osteoclast activation [3-5].
Skeletal maintenance occurs by a tightly coupled process
of bone remodeling consisting of a process of bone resorp-
tion by the osteoclasts followed by deposition of new bone
by the osteoblasts. Estrogen deficiency is known to
increase bone remodeling and the sustained increase in
bone turnover induces a faster bone loss. Hormone
replacement therapy (HRT) is known to restore this imbal-
ance [6] and reduce the incidence of spinal and peripheral
BMD = bone mineral density; BSP = bone sialoprotein; COMP = cartilage oligomeric matrix protein; CTX-I = C-terminal telopeptide fragments of 
type I collagen; CTX-II = C-terminal telopeptide fragments of type II collagen; DMARD = disease-modifying antirheumatic drug; E2 = estradiol; ELISA 
= enzyme-linked immunosorbent assay; ESR = erythrocyte sedimentation rate; HRT = hormone replacement therapy; ICTP = C-terminal telopeptide 
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fractures in healthy women [7,8] and also to improve bone
mass in women with rheumatoid arthritis (RA) [9,10].
Expression of estrogen receptors has been demonstrated
in osteoblastic cells [11], osteoclastic cells [12], and
human articular chondrocytes [13]. Estrogen decreases
osteoclast formation and activity and increases apoptosis
of osteoclasts [14,15]. Furthermore estrogen also seems
to have a stimulatory effect on bone formation by the oste-
oblasts [16]. Combined, these two effects are responsible
for the bone-protective effects of estrogen and they also
explain why women experience an accelerated bone loss
after the menopause.
Generalized bone loss in postmenopausal women with RA
will occur as a result of decreased estrogen levels acceler-
ating bone turnover and systemic bone loss and by the
inflammatory processes resulting in systemic increase of
several cytokines shown to up regulate systemic bone turn-
over. In addition, bone loss also takes place focally as a
consequence of the arthritic disease process. Markers of
bone turnover provide an integrated measure of systemic
turnover, and several studies have demonstrated significant
elevations in, especially, resorption markers in RA [17-20].
Elevated bone resorption markers are associated with
active progressive disease and decrease in bone mineral
density (BMD) [18-20].
We have recently reported that treatment with HRT for 2
years in postmenopausal women with RA significantly
improved BMD and also indicated a protective effect on
joint destruction [10]. The aim of this randomized, control-
led trial was to assess the effect of HRT in postmenopausal
RA on biochemical markers of bone and cartilage turnover,
the correlations between the markers and bone mass and
joint damage, and the associations between changes in
biochemical markers and changes in BMD and joint
destruction at 2 years. The a priori assumption was that the
HRT would induce a significant reduction of not only bone
turnover but also cartilage turnover, indicating a structure-
modifying therapeutic effect of HRT in RA.
We found that HRT reduced markers of both bone and car-
tilage metabolism and that the decrease in markers of bone
turnover was associated with BMD gain. The type I colla-
gen degradation marker ICTP (C-terminal telopeptide of
type I collagen) and the cartilage markers CTX-II (C-termi-
nal telopeptide fragments of type II collagen) and cartilage
oligomeric matrix protein (COMP) were associated with the
Larsen score at baseline. Of the markers tested, CTX-I (C-
terminal telopeptide fragments of type I collagen) reflected
bone turnover most sensitively.
Materials and methods
Patients and trial design
Five hundred ninety-two female patients with RA, aged 45–
65 years, were identified from rheumatology clinic patient
registers in Göteborg and Borås, Sweden. They were
invited by mail to participate in a 2-year clinical randomized,
single blind, controlled study. The women had to be post-
menopausal, defined as not having menstruated in the pre-
vious year and having a serum follicle-stimulating hormone
(FSH) level >50 IU/l (Diagnostic Products Corporation,
Los Angeles, CA, USA). Of the women who were sent the
letter inviting them to take part, 81% (478/592) replied.
The patients had to have active disease that met at least
two of the following criteria: at least six painful joints, at
least three swollen joints, an erythrocyte sedimentation rate
(ESR) ≥ 20 mm per hour, and C-reactive protein concentra-
tion ≥ 10 mg/l, and they had to fulfill the American Rheuma-
tism Association 1987 revised criteria for adult RA [21]. A
maximum daily dose of 7.5 mg of prednisolone was
accepted and intra-articular and intramuscular glucocorti-
costeroid injections were allowed during the study period.
The patients were not receiving and had not used in the
preceding 2 years drugs affecting bone metabolism (HRT
or bisphosphonates), except calcium and vitamin D3, which
were allowed. They had no contraindications to HRT. Three
hundred ninety (390/478) of the women could not partici-
pate for the following reasons: seventy-two of the women
were not postmenopausal and 19 did not fulfill the diagnos-
tic criteria for RA, 159 had been treated with HRT during
the preceding 2 years, 26 had a history of deep venous
thrombosis or embolism, 23 of cancer of the breast, uterus,
or ovaries, 18 had started disease-modifying antirheumatic
drugs (DMARDs) or glucocorticosteroid therapy within the
previous 3 months or had language problems or had moved
to other parts of Sweden, 6 were treated with bisphospho-
nates, and 67 did not want to participate. Eighty-eight
(23%) of the probands entered the study. Patients who
dropped out were included in calculations until their
withdrawal.
All patients gave their informed consent and the Ethics
Committee at the Göteborg University approved the study.
Treatment
Forty-one patients were allocated to the HRT group and 47
to the control group by simple randomization by an inde-
pendent research nurse. All patients were treated with a
daily dose of 500 mg calcium and 400 IU vitamin D3.
Women in the HRT group who were more than 2 years past
the menopause were given continuous treatment with 2 mg
estradiol (E2) plus 1 mg norethisterone acetate daily (23
patients). Patients who had had a hysterectomy were given
just 2 mg E2 (4 patients) and the remaining women were
given 2 mg E2 for 12 days, followed by 2 mg E2 plus 1 mg
norethisterone acetate for 10 days, followed by 1 mg E2 forAvailable online http://arthritis-research.com/content/6/5/R457
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6 days (14 women). The gynecologists examined all
patients at entry into the study and after 12 and 24 months.
The investigators in the rheumatology departments were
blinded to the identity of the treatment. Regular medication
for RA could be altered by the clinician but not by the
investigator.
Assessment of outcome variables
Venous blood and urine samples were obtained at study
entry and after 12 and 24 months; they were taken in the
morning after an overnight fast. The samples were stored at
-70°C until the time of analysis. Serum and urine samples
from all time points were analyzed simultaneously except
the ESR, which was measured consecutively.
Carboxy-terminal telopeptide fragments of type I collagen
Serum levels of CTX-I derived from bone resorption were
measured by a one-step ELISA (Nordic Bioscience A/S,
Herlev, Denmark) using two monoclonal antibodies specific
for a β-aspartate form of the epitope EKAHDGGR derived
from the carboxy-terminal telopeptide region of type I colla-
gen α1 chain [22,23]. The detection limit was 0.01 ng/ml
[23]. Intra- and inter-assay coefficients of variation of the
serum CTX-I assay were 5.4 and 6.2% respectively. All
samples were measured in duplicate and samples from the
same patient were measured on the same ELISA plate.
Samples were re measured if coefficients of variation
exceeded 15%.
Carboxy-terminal telopeptide of type I collagen
Radioimmunoassay was used for the quantitative determi-
nation in serum of the bone resorption marker ICTP (Orion
Diagnostica, Espoo, Finland). The detection limit of the test
was 0.5 µg/l and the intra-assay and interassay coefficients
of variation were <8% according to the manufacturer and
<6% in our laboratory.
Bone sialoprotein
An inhibition ELISA with a polyclonal antiserum raised
against human bone sialoprotein (BSP) was used for meas-
urement in serum of BSP, a marker reflecting bone turnover
[24]. The detection limit of the test was 2.5 ng/ml and the
intra-assay and interassay coefficients of variation were
<10%.
Carboxy-terminal propeptide of type I procollagen
Radioimmunoassay was used for the quantitative determi-
nation in serum of the collagen type I turnover marker PICP
(C-terminal propeptide of type I procollagen) (Orion Diag-
nostica). The detection limit of the test was 1.2 µg/l and the
intra-assay and interassay coefficients of variation were
<7% according to the manufacturer and <5% in our
laboratory.
Collagen type II degradation fragments
Urinary levels of CTX-II, reflecting cartilage breakdown,
were measured by a new competitive ELISA (CartiLaps;
Nordic Bioscience A/S, Herlev, Denmark) based on a
mouse monoclonal antibody raised against the EKGPDP
sequence of human type II collagen C-telopeptide. This
sequence is found exclusively in type II collagen and not in
other collagens, including type I collagen or other structural
proteins. The detection limit of the test was 0.15 ng/ml
[25]. Intra-assay and interassay coefficients of variation of
the urine CTX-II assay were 7.1% and 8.4% respectively.
Urinary CTX-II was corrected by the urinary creatinine con-
centration measured by a standard colorimetric method
and expressed as the ratio of CTX-II (ng) to urinary creati-
nine (mmol).
Cartilage oligomeric matrix protein
The cartilage-turnover marker COMP was measured in
serum by a sandwich ELISA based on two monoclonal anti-
bodies directed against separate antigenic determinants
on the human COMP molecule (AnaMar Medical, Lund,
Sweden). The detection limit of the test was 0.1 U/l and the
intra-assay and interassay coefficients of variation were
<5%. The serum concentrations of COMP obtained by this
assay are highly correlated with serum levels obtained by
the original inhibition assay (r values >0.9 in RA samples)
[26] (Saxne T and Heinegård D, unpublished).
Estradiol
E2 levels in serum were measured (around 12 hours after
tablet intake) at baseline and yearly thereafter using radio-
immunoassay (Clinical Assays™ DiaSorin, Vercelli, Italy).
The detection limit of the test was 18 pmol/l.
Bone mineral density
BMD in the left forearm, left hip, and lumbar spine was
measured at study entry and at 12 and 24 months by dual-
energy x-ray absorptiometry (DXA) with Hologic QDR-
4500A® (Hologic, Bedford, MA, USA).
Radiographs
Radiographs of the hands, wrists, and distal part of the feet
were obtained at baseline and after 12 and 24 months.
Forty joints in the hands and feet were scored (in the hands,
proximal interphalangeal joints of digits 1–5, metacar-
pophalangeal joints of digits 1–5, wrist areas 1–4; and in
the feet, the interphalangeal joints of digit 1 and the meta-
tarsophalangeal joints of digits 1–5). The radiographs were
masked for identity and sequence and they were evaluated
by Dr Arvi Larsen [27], who was unaware of the treatments
of the patients. Each joint was scored from 0 (normal) to 5
(maximal destruction). The scores for each patient were
summarized and then divided by the number of examined
joints to give the patient's mean Larsen score, ranging from
0 to 5.Arthritis Research & Therapy    Vol 6 No 5    Forsblad d'Elia et al.
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Disease Activity Score 28
DAS 28 [28] was assessed at all check points, calculated
by the following formula: DAS 28 = 0.56 TJC1/2 + 0.28
SJC1/2 + 0.70lnESR + 0.014GH, where TJC gives the
tender joint count, SJC, the swollen joint count, and GH,
the patient's assessment of general health using a Visual
Analogue Scale of 100 mm.
Statistical analysis
The primary end points of the original study were radio-
graphic progression of joint damage and change in BMD
over the 2-year observation period [10]. Biochemical
marker measurements were added as secondary end
points. For power calculation concerning the number of
patients needed to detect a significant difference of BMD
between study groups at the significance level 0.05, a two-
tailed test with 90% power was conducted. The number of
patients included in the trial was well sufficient. The data
found for the biomarkers were not normally distributed, and
nonparametrical tests were therefore used. Comparisons
between the groups were made using the Mann–Whitney
U test, and changes within the treatment groups by the Wil-
coxon rank sum test. Associations between biochemical
markers, BMD, and joint destruction were assessed by
Spearman's rank correlation test. A χ2 test was used to
compare proportions. To account for the multiple compari-
sons made in the statistical assessment of the data, actual
P values are shown. All tests were two-tailed and P ≤ 0.05
was considered statistically significant.
Results
Patient population
The two patient groups were comparable with respect to all
variables tested at baseline. The age (years) in the HRT
group was 57.0 ± 5.5 (mean ± SD) and in the controls,
58.1 ± 4.7, and the disease durations (years) were 16.4 ±
11.9 and 15.5 ± 11.7, respectively. Thirty-four (83%) of the
women in the HRT group had positive tests for rheumatoid
factor, compared with 40 (85%) of the controls. Prior drug
use was similar in the two groups at the start of the study,
with disease-modifying antirheumatic drug (DMARD) use in
34 patients (83%) of the HRT group and 37 (79%) of the
controls (P = 0.58). Ten (24%) patients in the HRT group
and 9 (19%) in the control group were treated with oral glu-
cocorticosteroids (P = 0.55) at a mean dosage of 4.6 mg
of prednisolone, and 17 (44%) and 13 (28%), respectively,
were treated with methotrexate (P = 0.14). No patient used
biologic agents, since they were not available when the
study started. The proportions of patients treated with
DMARDs, methotrexate, and corticosteroids were equal in
the HRT and control groups at all check points during the
study. No significant differences between the treatment
groups were found regarding change in DMARDs, or the
amounts of corticosteroids injected intra-articularly and
intramuscularly. For further information, please see a previ-
ous report [10]. There were no significant differences
regarding ESR, E2, or biochemical markers of bone and
cartilage metabolism between the two study groups at
baseline (Table 1).
Six (15%) patients in the HRT group and 2 (4%) in the con-
trol group withdrew from the study before completing the 2
years (Table 2). No serious side effects were observed. For
some patients, incomplete sample sets were available for
analysis of biochemical markers. The number of samples
available for each analysis is presented in Table 1.
The impact of HRT on biochemical markers of bone and 
cartilage turnover
As reported previously, BMD increased significantly, by
3.6% in the forearm, 4.0% in the total hip, and 7.1% in the
lumbar spine in the HRT group [10]. Furthermore, there
was an indication of a joint-protective effect of the HRT
treatment [10]. The results of the bone and cartilage bio-
chemical marker analyses are shown in Table 1.
Markers of bone turnover
HRT caused a pronounced decrease in the collagen type I
degradation marker, CTX-I, both when the HRT and control
groups were compared (P < 0.001) and within the HRT
group (P < 0.001) (Fig. 1a). CTX-I in the HRT group was
reduced by 62 ± 5% (mean ± SEM) after 12 months and
53 ± 6% after 24 months. In the control group a decrease
of 3 ± 13% and an increase of 12 ± 13% was observed
after 12 and 24 months, respectively.
HRT resulted also in a significant (P = 0.035) but less pro-
nounced reduction in the other collagen type I degradation
product, ICTP. The average percentage reduction of this
marker was 5 ± 7% after 12 months and 5 ± 5% after 24
months in the HRT group. A significant increase (P  =
0.002) of ICTP was found in the controls, by an average of
21 ± 6% after 12 months and 31 ± 10% after 24 months.
BSP, which is a bone-specific protein enriched in the carti-
lage–bone interface, increased significantly (P = 0.023) in
the control group but remained unchanged in the HRT
group.
The marker of bone formation, PICP, decreased signifi-
cantly in comparison with the controls (P = 0.005) as well
as within the HRT group (P < 0.001) by the end of the first
year. After the second year, a significant decrease was
found within the HRT group (P = 0.021) in comparison with
baseline values. PICP decreased by 23 ± 4% in the first
year and by 10 ± 4% the second year in the HRT-treated
women.Available online http://arthritis-research.com/content/6/5/R457
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Markers of cartilage turnover
The HRT group presented a marked decrease in serum lev-
els of COMP, both between the HRT and control group (P
= 0.003) and within the HRT group (P  = 0.003). The
Table 1
The impact of hormone replacement therapy (HRT) on biochemical markers of bone and cartilage metabolism
At study entry At 12 months At 24 months
CTX-I (ng/ml) HRT 0.59 ± 0.37 (35) 0.21 ± 0.15 (32) †††,‡‡‡ 0.25 ± 0.16 (33) †††,‡‡‡
Controls 0.63 ± 0.34 (46) 0.53 ± 0.41 (46) ‡ 0.66 ± 0.66 (42)
ICTP (µg/l) HRT 5.1 ± 2.1 (35) 4.7 ± 2.2 (29) ††,‡ 4.9 ± 2.4 (33) †††,‡
Controls 4.6 ± 1.7 (44) 5.8 ± 3.4 (46) ‡ 6.5 ± 5.4 (44) ‡‡
BSP (ng/ml) HRT 119.3 ± 39.6 (41) 126.8 ± 34.1 (33) 127.6 ± 47.8 (34)
Controls 126.7 ± 35.7 (47) 139.5 ± 46.5 (47) ‡ 143.1 ± 45.3 (45) ‡
PICP (µg/l) HRT 132.8 ± 40.0 (34) 104.0 ± 26.9 (29) ††,‡‡‡ 121.0 ± 31.9 (34) ‡
Controls 133.1 ± 42.7 (44) 132.6 ± 50.2 (46) 133.2 ± 40.0 (44)
COMP (U/l) HRT 11.0 ± 2.6 (39) 10.1 ± 2.9 (33) †,‡ 9.8 ± 2.7 (34) ††,‡‡
Controls 11.3 ± 3.2 (47) 11.6 ± 2.8 (47) 11.8 ± 2.7 (45)
CTX-II (ng/mmol) HRT 1.1 ± 1.3 (41) 0.8 ± 0.8 (36) 0.9 ± 1.1 (34) ‡
Controls 1.2 ± 1.4 (44) 1.3 ± 1.5 (46) 1.1 ± 0.9 (44)
Estradiol (pmol/l) HRT 47.7 ± 47.9 (31) 177.6 ± 139.4 (25) †††,‡‡‡ 176.1 ± 124.0 (31) †††,‡‡‡
Controls 37.2 ± 25.5 (40) 38.3 ± 33.2 (41) 37.8 ± 39.2 (38)
ESR (mm) HRT 30.8 ± 19.1 (41) 29.0 ± 18.8 (35) 24.3 ± 13.1 (35) †,‡‡
Controls 26.5 ± 15.1 (46) 27.4 ± 19.8 (45) 26.3 ± 17.5 (44)
DAS 28 HRT 5.2 ± 1.0 (41) 4.4 ± 1.1 (35) ‡‡‡ 3.9 ± 1.0 (35) †,‡‡‡
Controls 5.3 ± 1.0 (46) 4.8 ± 1.3 (45) ‡‡ 4.5 ± 1.1 (44) ‡‡‡
Values are means ± SD. Numbers of patients with available data are shown in parentheses. †P <0.05 for the comparison with controls from 
baseline with respects to differences; ††P < 0.01 for the comparison with controls from baseline with respects to differences; †††P < 0.001 for the 
comparison with controls from baseline with respects to differences; ‡P < 0.05 for the comparison with baseline with respects to differences; ‡‡P 
< 0.01 for the comparison with baseline with respects to differences; ‡‡‡P < 0.001 for the comparison with baseline with respects to differences. 
BSP, bone sialoprotein; COMP, cartilage oligomeric matrix protein; CTX-I, type I collagen C-telopeptide fragments; CTX-II, type II collagen C-
telopeptide; DAS, Disease Activity Score 28 [28]; ESR, erythrocyte sedimentation rate; ICTP, C-terminal telopeptide of type I collagen, PICP, C-
terminal propeptide of type I procollagen.
Table 2
Reasons for withdrawal from the study
Patients receiving HRT Controls
Year Reason No. Reason No.
First year Hyperperspiration 1
Hyperparathyroidism 1
Nausea 2
Nausea and weight gain 1
Second year Overlap syndrome 1 Started HRT 1
Cancer of the thyroid 1
Total 62
HRT, hormone replacement therapy.Arthritis Research & Therapy    Vol 6 No 5    Forsblad d'Elia et al.
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percentage reduction was 9 ± 4% in the HRT group, com-
pared with an increase of 7 ± 4% in the controls at 2 years
(Fig. 1b).
The urinary marker of cartilage degradation, CTX-II, had
decreased significantly at 2 years within the HRT group (P
= 0.023) in comparison with baseline values.
Correlations at baseline
The correlations at baseline are shown in Table 3. CTX-I
was inversely associated with BMD in both the forearm (P
= 0.011) and the total hip (P = 0.024) and was positively
associated with ICTP (P = 0.001) and PICP (P < 0.001).
ICTP, besides showing a positive correlation with CTX-I,
was inversely correlated with BMD in the forearm (P =
0.029) and total hip (P = 0.003) and was positively corre-
lated with ESR (P = 0.013), CTX-II (P < 0.001) and the
Larsen score (P < 0.001).
PICP, in addition to its strong correlation with CTX-I, was
inversely correlated with BMD in the forearm (P = 0.017)
and was positively correlated with COMP (P = 0.020).
CTX-II was positively correlated with the Larsen score (P =
0.001) and ESR (P = 0.018) as well as with ICTP.
COMP, in addition to its correlation with PICP, was also
correlated with BMD in the lumbar spine (P = 0.009) and
with the Larsen score (P = 0.014).
Long-term changes in biochemical markers correlated 
with changes in BMD
The alterations in biochemical markers of bone and carti-
lage metabolism from baseline to 24 months were corre-
lated with each other and with the changes in BMD and
radiological destruction during the same period (Table 4).
A decrease in CTX-I was correlated with increased bone
mass in the total hip (P < 0.001) and lumbar spine (P <
0.001) and with a reduction in ICTP (P < 0.001), PICP (P
= 0.005) and ESR (P = 0.019). Because E2 and bone
mass changes were strongly correlated, the partial correla-
tion coefficients adjusting for the effect of E2 changes were
calculated, in order to assess if there were independent
correlations between CTX-I and BMD. The coefficients
remained significant concerning CTX-I and the total hip (-
0.308, P = 0.023) and CTX-I and the lumbar spine (-0.280,
P = 0.04).
A reduction in ICTP was correlated with improved BMD in
the lumbar spine (P = 0.002) and total hip (P = 0.027) and
with a decrease in ESR (P = 0.006), CTX-II (P = 0.001),
and COMP (P = 0.005), besides the correlation with CTX-
I. The correlations between changes in ICTP and BMD in
the spine and hip remained significant in the hip (-0.301, P
= 0.023) but not in the spine (-0.175, P = 0.194) after
adjustment had been made for the effect of changed E2 lev-
els.
Figure 1
The effects of hormone replacement therapy (HRT) on serum markers of bone and cartilage metabolism The effects of hormone replacement therapy (HRT) on serum markers of bone and cartilage metabolism. (a) Effect of HRT on serum (S) levels of 
type I collagen C-telopeptide (CTX-I). (b) Effect of HRT on serum levels of cartilage oligomeric matrix protein (COMP). Values are the medians (hor-
izontal line), interquartile ranges (box), and ranges (whiskers). Circles (outliers) represent cases with values between 1.5 and 3 box lengths, and 
boxes (extremes) represent values more than 3 box lengths from the upper or lower edge of the box. Statistical differences between the groups and 
within each group are given.Available online http://arthritis-research.com/content/6/5/R457
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A decrease in PICP was correlated with an increase in
BMD in the total hip (P = 0.030) and with reduction in
COMP (P = 0.006) and the Larsen score (P = 0.002) in
addition to the correlation with CTX-I. The correlation
between changes in PICP and BMD in the hip remained
significant (-0.260, P = 0.049) after adjusting for the effect
of changed E2 levels.
Decrease in CTX-II, in addition to the correlation with ICTP,
was also strongly correlated with decreased ESR (P  <
0.001).
Short-term changes in markers correlated with long-
term changes in BMD
We also investigated whether the above markers, which
were significantly correlated with the outcome of BMD and
the Larsen score also, could be predictive when the short-
term changes, from baseline to 12 months, were used
instead in the correlation analyses. We found that the
changes in serum levels of CTX-I over the first 12 months
were inversely correlated with the alteration in BMD in the
total hip (P < 0.001), lumbar spine (P < 0.001), and fore-
arm (P = 0.050). The percentage change in CTX-I during
Table 3
Baseline correlations between biochemical markers of bone and cartilage metabolism, bone mineral density, and radiographic joint 
destruction
Biochemical 
marker
ESR CTX-I ICTP BSP PICP CTX-II COMP BMD,
forearm
BMD,
total hip
BMD,
lumbar spine
Larsen 
score
ESR - 0.111 0.280* 0.088 0.026 0.257* 0.095 -0.171 -0.195 -0.100 0.500***
CTX-I 0.111 - 0.366** 0.194 0.401*** 0.129 0.099 -0.293* -0.253* -0.187 0.182
ICTP 0.280* 0.366** - -0.120 0.138 0.472*** 0.201 -0.255* -0.322** -0.129 0.449***
BSP 0.088 0.194 -0.120 - 0.195 0.047 -0.072 0.100 0.012 0.076 -0.045
PICP 0.026 0.401*** 0.138 0.195 - 0.069 0.264* -0.281* -0.205 -0.218 0.103
CTX-II 0.257* 0.129 0.472*** 0.047 0.069 - 0.160 -0.075 -0.170 0.073 0.361**
COMP 0.095 0.099 0.201 -0.072 0.264* 0.160 - 0.099 0.187 0.281** 0.271*
Estradiol 0.015 -0.077 0.020 0.020 -0.041 0.120 0.171 0.209 0.185 0.255* 0.008
Radiographic joint destruction was assessed using the Larsen score [27]. *P < 0.05; **P < 0.01; ***P < 0.001. BMD, bone mineral density; BSP, 
bone sialoprotein; COMP, cartilage oligomeric matrix protein; CTX-I, type I collagen C-telopeptide fragments; CTX-II, type II collagen C-
telopeptide; ESR, erythrocyte sedimentation rate; ICTP, C-terminal telopeptide of type I collagen; PICP, C-terminal propeptide of type I 
procollagen.
Table 4
Correlations between changes over 2 years in biochemical markers of bone and cartilage metabolism and in bone mineral density 
and radiographic joint destruction
∆ESR ∆CTX-I ∆ICTP ∆BSP ∆PICP ∆CTX-II ∆COMP ∆BMD, 
forearm
∆BMD, 
total hip
∆BMD, 
lumbar 
spine
∆Larsen 
score
∆ESR - 0.276* 0.327** 0.004 -0.031 0.407*** 0.188 -0.093 -0.092 -0.145 0.068
∆CTX-I 0.276* - 0.535*** 0.189 0.348** 0.119 0.184 -0.234 -0.507*** -0.501*** 0.083
∆ICTP 0.327** 0.535*** - 0.167 0.040 0.401** 0.338** -0.239 -0.271* -0.372** -0.043
∆BSP 0.004 0.189 0.167 - -0.092 -0.029 0.004 -0.056 -0.163 0.032 -0.079
∆PICP -0.031 0.348** 0.040 -0.092 - 0.042 0.328** -0.138 -0.266* -0.222 0.392**
∆CTX-II 0.407*** 0.119 0.401** -0.029 0.042 - 0.190 -0.094 -0.055 -0.146 0.052
∆COMP 0.188 0.184 0.338** 0.004 0.328** 0.190 - -0.190 -0.204 -0.157 -0.027
∆Estradio
l
-0.079 -0.373** -0.301* -0.092 -0.160 -0.094 -0.243 0.067 0.491*** 0.483*** 0.063
Radiographic joint destruction was assessed using the Larsen score [27]. *P < 0.05; **P < 0.01; ***P < 0.001. BMD = bone mineral density; 
BSP, bone sialoprotein; COMP, cartilage oligomeric matrix protein; CTX-I, type I collagen C-telopeptide fragments; CTX-II, type II collagen C-
telopeptide; ESR, erythrocyte sedimentation rate; ICTP, C-terminal telopeptide of type I collagen; PICP, C-terminal propeptide of type I 
procollagen.Arthritis Research & Therapy    Vol 6 No 5    Forsblad d'Elia et al.
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the first year correlated with the change in BMD in the lum-
bar spine during the whole trial is shown in Fig. 2.
The short-term change in ICTP was inversely associated
with altered bone mass in the forearm (P = 0.038) and lum-
bar spine (P = 0.023), and the change in PICP was corre-
lated with the modification in the Larsen score (P = 0.024)
and inversely with BMD in the total hip (P = 0.002), lumbar
spine (P = 0.002), and forearm (P = 0.017).
The short-term change in E2 was also associated with the
2-year change in bone mass in the total hip (P = 0.006) and
lumbar spine (P = 0.007), so we adjusted the above mark-
ers for the effect of alterations in serum levels of estrogen
at these measurement sites. The correlations remained sig-
nificant after adjustment for the influence of estrogen.
Discussion
The main objective of the present study was to analyze the
effects of HRT on biochemical markers of both bone and
cartilage metabolism in RA in postmenopausal women.
This report is the first to show that HRT resulted in reduc-
tion of markers of both bone and cartilage turnover in
women with RA. We also wanted to evaluate associations
between the markers and bone mass and the Larsen score
at baseline and to see if the changes in markers could pre-
dict BMD and joint destruction. There were significant cor-
relations between several biochemical markers and bone
mass and radiological status at entry into the study. Addi-
tionally, decreases in markers of bone metabolism were
associated with improved bone mass. These findings sup-
port our previous results showing improved bone mass in
the forearm, total hip, and lumbar spine, and also indicated
a joint-protective effect of HRT in patients with progressive
erosive RA [10]. The ESR also decreased and DAS 28 was
decreased significantly more in the HRT group than in the
controls, as has been shown in more detail in a previous
work [10]. However, in view of the recent trials of HRT use
among healthy postmenopausal women, showing, for
example, an increased risk of cardiovascular events and
breast carcinoma [29], there is a need to be cautious about
HRT. It is hardly possible to generalize the results from
studies of healthy postmenopausal women to patients with
RA, a chronic inflammatory disease. In RA patients, the sys-
temic inflammation seems to be more important than tradi-
tional risk factors in the development of coronary heart
disease, and it may be that HRT use could find better
acceptance in RA than among otherwise healthy postmen-
opausal women, but this issue requires further study [30].
Some limitations of the present study should be mentioned.
Corrections have not been made for multiple comparisons,
since the findings seem biologically reasonable and in
accordance with our a priori hypothesis. Yet, one must be
cautious about significances with P values at the <0.05
level, which theoretically could have occurred by chance
since quite a lot of tests have been performed. It is also
important to take into account that the biochemical markers
that we have analyzed are not completely specific for bone
or articular cartilage, because minor amounts of these
markers may also be released from other tissues. However,
we estimate on the basis of previous reports that they
reflect bone and cartilage metabolism well enough to be
able to follow and assess bone and cartilage turnover
[31,32].
Type I collagen comprises more than 90% of the organic
bone matrix. Some other tissues also contain type I colla-
gen – for example, skin, tendon, and cornea – but bone has
a much higher proportion and a much higher turnover of
this protein. Type I collagen has a triple-helix structure.
Crosslinking by pyridinoline or deoxypyridinoline occurs
between residues on the nonhelical carboxy-terminal or
amino-terminal ends, termed telopeptides, and the helical
portion of an adjacent collagen [33]. During osteoclastic
bone resorption, cathepsin K and other proteases release
peptide bound crosslinks, attached to fragments of C-ter-
minal (CTX) or N-terminal (NTX) telopeptides [33,34]. The
crosslinks can be measured in the urine and serum as an
index of bone resorption. Cathepsin K, which is a major
osteoclast-derived protease, directly generates the frag-
ments measured in the CTX-I assay. Another assay specific
for fragments of the collagen type I C-telopeptide, ICTP,
results primary from nonosteoclastic matrix-metalloprotein-
Figure 2
Short-term changes in serum (S) levels of type I collagen C-telopeptide  (CTX-I) correlated with long-term changes in bone mineral density  (BMD) in the lumbar spine Short-term changes in serum (S) levels of type I collagen C-telopeptide 
(CTX-I) correlated with long-term changes in bone mineral density 
(BMD) in the lumbar spine. The percentage change the first year is plot-
ted against the change in BMD after 2 years in the hormone replace-
ment therapy (HRT) and control group. A regression line is inserted 
showing the significant inverse association.Available online http://arthritis-research.com/content/6/5/R457
R465
ase-mediated degradation of type I collagen [34]. In
accordance with the specificity of the type I collagen mark-
ers, the CTX-I assay has previously been shown to provide
a significant response to antiresorptive therapies, including
HRT [22,23,33,35]. In addition, strong associations
between levels of CTX-I and changes in this marker and
subsequent change in BMD have been demonstrated [22].
The CTX-I marker has been less used in RA, but some
recent studies have reported that high levels of CTX-I and
CTX-II, reflecting bone and cartilage degradation, respec-
tively, were associated with an increased risk of radiologi-
cal progression in RA [18,20,36].
We found that CTX-I had decreased significantly in the
HRT group, by 62% and 53% at 1 and 2 years, respec-
tively. This decrease is comparable to the effect of HRT in
healthy postmenopausal women [37]. A small reduction of
CTX-I was also noticed in the control group at the end of
first year, which possibly could be due to the treatment with
calcium and vitamin D3. CTX-I was inversely correlated with
the bone mass in forearm and total hip, and both the 1- and
2-year changes in CTX-I were associated with the 2-year
changes in BMD in the lumbar spine and total hip. In addi-
tion, the change in CTX-I was associated with a change in
serum levels of E2, suggesting a biological association
between the two parameters. The results imply that in RA,
also, serum CTX-I provides a good assessment of treat-
ment responses to antiresorptive therapy such as HRT
[18,20,36].
We also measured ICTP, which decreased by only 5% in
the HRT group, in accord with the findings of previous stud-
ies showing similar weak responsiveness of this marker to
HRT treatment in healthy postmenopausal women [23].
ICTP increased significantly in the controls, for reasons of
which we are not certain. In a previous study of the effect
of HRT on ICTP in RA, no change in ICTP was found [38].
These results may be considered to be in accord with the
biochemical background of the markers where CTX-I is
generated, whereas ICTP is destroyed by cathepsin-K-
mediated degradation of the organic bone matrix [34]. At
baseline, ICTP was correlated strongly with the Larsen
score and to a lesser extent with the ESR, an observation
that is in line with findings by others of increased serum lev-
els of ICTP in active RA [39,40].
Type I collagen is synthesized by osteoblasts as a precur-
sor protein termed procollagen I. The carboxy-terminal and
amino-terminal ends of procollagen I are removed during
fibril formation before type I collagen is incorporated into
the bone matrix. This cleavage yields two extension pep-
tides, PICP and procollagen I amino-terminal propeptide
(PINP), which are used as markers of bone formation
[ 3 1 , 3 3 ] .  I n  t h i s  s t u d y ,  w e  a n a l y z e d  P I C P .  T h e  m a r k e r
decreased significantly during the first year in the HRT
group compared with controls, as has previously been
found by Lems and co-workers [38]. The reduction was fol-
lowed by a significant increase within the HRT group dur-
ing the second year (data not shown), which might indicate
an anabolic effect on the osteoblasts by HRT, in line with
our previous findings of an increase in insulin-like growth
factor 1 in the HRT group [41]. PICP correlated signifi-
cantly with CTX-I and COMP and inversely with bone mass
in the forearm at baseline. The 1- and 2-year decreases in
PICP-I were associated with a reduction in COMP levels,
improved BMD, and a beneficial effect on the Larsen score.
The findings suggest that PICP together with CTX-I reflects
the rate of bone turnover, in accord with the findings of
Cortet and co-workers [40].
BSP accounts for about 10% of the noncollagenous pro-
teins in bone and is in particular enriched at cartilage–bone
interfaces. The function of the protein is not known,
although a role in mineralization has been proposed
[24,42,43]. In RA, BSP has been shown to be increased in
serum, and the concentration of BSP in synovial fluid was
correlated with the degree of knee joint damage in RA and
was thus considered to reflect tissue breakdown [24]. In a
prospective study, it was found that HRT decreased BSP
in healthy postmenopausal women [43]. In our study, HRT
exerted a suppressive effect, apparent as an increase of
BSP in the control group but not in the HRT group. Neither
the baseline levels nor the alterations in BSP were associ-
ated with bone mass or the Larsen score or its changes
during the trial. This contrasts with the results for other
bone markers and may be due to the restricted distribution
of BSP within the tissue.
Collagen type II is the major structural protein of cartilage,
comprising more than 50% of the protein in this matrix [32].
Type II collagen is synthesized by chondrocytes and
degraded by proteolytic enzymes secreted by the chondro-
cytes and synoviocytes, including matrix metalloprotein-
ases. The CTX-II marker derived from degradation of type II
collagen was measured as an index of cartilage turnover.
Previous studies have shown that CTX-II levels in the urine
are elevated in patients with osteoarthritis and RA
[20,25,36]. Lehmann and co-workers showed that antire-
sorptive treatment of postmenopausal women with a
bisphosphonate, ibandronate, decreased not only CTX-I
but also CTX-II [44]. This indicates a chondroprotective
effect of this class of compounds, which has also been
suggested by recent in vitro [45] and in vivo [46] studies.
Of interest to our study is the fact that HRT treatment of
healthy postmenopausal women has also been shown to
be associated with significant lower CTX-II levels, indicat-
ing an effect of HRT on cartilage turnover [47]. In the
present investigation, CTX-II in the urine decreased signifi-
cantly within the HRT group, a finding that implies that HRT
has a protective effect on cartilage. CTX-II was also corre-Arthritis Research & Therapy    Vol 6 No 5    Forsblad d'Elia et al.
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lated with ESR, ICTP, and the Larsen score at entry into the
study, and the change in CTX-II at the end of 2 years was
associated with the changes in ESR and ICTP, indicating
an association with the inflammatory activity and processes
of structural damage in the disease.
COMP is a 524-kDa, homopentameric, extracellular-matrix
protein and it constitutes 0.5–1% of the wet weight of car-
tilage and is released from cartilage during the erosive
process [26]. Its biological function is still unclear, but find-
ings suggest that COMP may be involved in regulating fibril
formation and maintaining the integrity of the collagen net-
work. It was initially found in cartilage [48], but more
recently it has also been found to be secreted from other
tissues, such as synovial fibroblasts [49]. COMP has been
shown to be increased in serum at disease onset in RA
patients who developed large-joint destruction [50]. In
early RA, high serum levels have recently been found to
correlate also with future small-joint damage [51]. Moreo-
ver, neutralization of tumour necrosis factor α decreased
serum levels of COMP in RA [52]. We show decreasing
serum levels of COMP by HRT in this longitudinal study.
COMP decreased significantly both within the HRT group
and in comparison with the controls. As was discussed in
a previous report [5], an explanation of the positive associ-
ation between COMP and BMD at entry into the study
could be due to a strong relation between osteoporosis
and severe joint damage with decreased presence of artic-
ular cartilage and consequently reduced cartilage turnover.
Both biochemical markers reflecting cartilage metabolism
were associated with the Larsen score at baseline but no
correlations between changes in the markers and subse-
quent changes in the Larsen scores were found. One plau-
sible reason for this lack of association may be that the
Larsen did not change at all during the trial in about 40% of
the patients; this fact reduces the probability of finding any
significant associations between changes.
Conclusion
We found in this randomized, controlled trial that treatment
with HRT in postmenopausal women with established RA
reduced markers of bone turnover as well as of cartilage
metabolism. The decrease in bone turnover markers CTX-I,
ICTP, and PICP were associated with improved bone mass
after 2 years, with CTX-I providing the most sensitive prog-
nostic value. Baseline measures of ICTP and the markers of
cartilage turnover, CTX-II and COMP, were correlated with
the Larsen score and decreased during HRT treatment.
Thus, specific biochemical markers of bone and cartilage
turnover may be useful for assessing novel treatment
modalities in arthritis, concerning both joint protection and
prevention of osteoporosis.
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